Introduction
Lung transplantation (LTx) is a well-established treatment in a number of end-stage lung diseases that increases quality of life and survival corresponding to a one-, five-, and ten-year survival rate of 90 %, 60-70 %, and 40-50 %, respectively. Most patients die of chronic lung allograft dysfunction (CLAD) which affects approximately 50 % of all lung transplant recipients after five years. Since 2010 growing attention has been paid to the phenotyping of CLAD as bronchiolitis obliterans syndrome (BOS) and restrictive CLAD (rCLAD). BOS is defined as a persistent decline in forced expiratory volume in one second (FEV 1 ) of 20 % compared to the average of the two best post-transplant values, whereas rCLAD is defined as a combined decline in FEV 1 and total lung capacity (TLC) of more than 10 % compared to the best post-transplant baseline values (Sato M et al. J Heart Lung Transplant. 2011; 30:735-42) . BOS may respond well to pharmacological treatment, whereas there is not yet any documented rCLAD treatment. Also, in contrast to BOS, rCLAD is associated with pleuroparenchymal fibroelastosis (PPFE) on high-resolution computed tomography (HRCT) and has an inferior survival rate compared to BOS (Verleden SE et al. J Heart Lung Transplant. 2014; 33:270-7) .
Identification of pleura pathology and fibrosis in interstitial lung diseases, such as idiopathic PPFE, can be identified using lung ultrasound (LUS) in the presence of pleural thickening and the so-called interstitial syndrome (IS), which, in accordance Case Report Lung Ultrasound -A Novel Diagnostic Tool To Phenotype Chronic Lung Allograft Dysfunction?
with the international evidence-based guideline for point-of-care LUS, is defined as more than 3 B-lines in more than 2 anterior and/or lateral zones on each hemithorax (Volpicelli G et al. Intensive Care Med. 2012; 38:577-91) . As a radiation-free and fast procedure which is easily performed with minimal discomfort for the patient, LUS excels in a clinical setting.
Below we describe LUS findings in a lung transplant recipient compatible with PPFE findings on an HRCT, which in combination with lung physiology was in favor of rCLAD.
Case Description
A male in his mid-fifties with bilateral lung transplant due to alfa 1 antitrypsin deficiency with emphysema experienced unantici- for the deterioration in lung function were found. In this way the combination of radiological imaging (HRCT and LUS) and lung physiology facilitated the diagnosis of rCLAD (▶ Fig. 2, 3) . The described HRCT and LUS findings were not identified in the lower lobes (▶ Fig. 4 ).
Discussion
To our knowledge, this is the first case report describing the use of LUS in an LTx setting to support a diagnosis of rCLAD. As this is a case report, we are unable to determine whether any of our findings can be considered specific of PPFE. Reddy et al. dscribed specific HRCT findings in the form of pleuroparenchymal thickening in the upper lobes (Reddy TL et al. Eur Resp J 2012: 40; 377-85) . Since pleuroparenchymal thickening can be identified using HRCT, the same findings might be extrapolated when assessing patients with LUS. However, a major limitation is that LUS cannot be used to assess the underlying aerated lung tissue. Possible pitfalls could therefore be other conditions with pleural thickening predominantly affecting the upper lobes (e. g., chronic pulmonary aspergillosis (CPA), pulmonary sarcoidosis stage IV, and chronic hypersensitivity pneumonitis (cHP)). Nevertheless, when assessing the thickened pleura in the upper lobes, some signs may possibly be used to differentiate PPFE from other conditions. CPA may cause apical pleural thickening to the same extent as PPFE, but as opposed to PPFE the pleural thickening is relatively homogeneous. When CPA is assessed using LUS, the thickened pleura may thus appear homogeneous with fragmentation being less pronounced. In pulmonary sarcoidosis stage IV and cHP, the pleura may appear thickened and fragmented in the upper lobes. However, based on the study by Reddy et al., we expect the extent of pleural thickening to be more severe in PPFE than in sarcoidosis stage IV and cHP. In studies assessing the use of LUS in interstitial lung diseases, the predominant findings are B-lines and a thickened and fragmented pleura line (Reissig A et al. Respiration 2014; 87:179-89) . The fragmented pleura line most often appears hyperechoic and not hypoechoic as was the case in the presented case. As such, LUS findings in the form of relatively marked pleural thickening and concomitant fragmentation in the upper lobes may be specific LUS findings compatible with PPFE.
HRCT is a mandatory radiological modality in the examination of CLAD in combination with lung physiology and sometimes invasive diagnostic procedures. However, based on the above-mentioned reflections, LUS may be considered as an alternative add-on diagnostic modality to HRCT in order to support the distinction and phenotyping of CLAD subtypes as BOS and rCLAD. Due to the inferior prognosis of rCLAD, a potential association between HRCT verified PPFE and LUS findings suggestive of PPFE in rCLAD patients is also of prognostic interest, and furthermore, sup-
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ports the use of LUS as a potential monitoring tool for rCLAD (i. e., PPFE) progression.
In this case the supplemental LUS findings did not influence the clinical management but did provide the clinician with more specific knowledge regarding a worse prognosis than BOS. Such knowledge may ultimately provide better timing of overall management including long-term oxygen therapy, experimental treatments, re-transplantation, and palliation.
As there is no evidence on this topic, prospective studies validating LUS with HRCT findings as the gold standard in a series of cases with CLAD are warranted to yield more information about the role of LUS in a clinical context. 
